Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney

Key inclusion criteria * Recipients of first kidney transplant Key exclusion criteria * Those at high risk for acute allograft rejection, including those who receive a second or more renal transplant, those with a history of panel reactive antibody levels \>20%, and those considered by investigators to be at relatively higher risk for acute rejection * Human leukocyte antigen-identical donor-recipient pairs * Cold ischemia time \>36 hours (donor kidney) * Participants who are positive for hepatitis C antibody, on polymerase chain reaction, for hepatitis B surface antigen, and for human immunodeficiency virus * A positive purified protein derivative tuberculosis test (test performed within 1 year of enrollment), unless previously vaccinated with Bacille-Calmette-Guérin or those who had a history of adequate chemoprophylaxis * Any active infection that would normally exclude transplantation * Recipients of multiple organ transplants * Donor age \>60 or \<6 years or donors whose hearts were not beating * Recipients with underlying renal disease of (due to risk of rapid disease recurrence in the allograft): focal segmental glomerulosclerosis, Type I or II membranoproliferative glomerulonephritis, or hemolytic uremic syndrome/ thrombotic thrombocytopenic purpura * A positive T-cell lymphocytoxic crossmatch using donor lymphocytes and recipient serum * A history of true allergy to intravenous iodinated roentgenographic contrast agents * Participants with life expectancy severely limited by disease state or other underlying medical condition * A history of cancer (other than nonmelanoma skin cell cancers cured by local resection) within the last 5 years * Mammogram film with any clinically significant abnormality requiring further investigation or biopsies * History of substance abuse (drug or alcohol) or psychotic disorders that were not compatible with adequate study follow-up * A currently functioning, nonrenal transplant * Previous treatment with basiliximab for any reason * Active peptic ulcer disease, chronic diarrhea, or gastrointestinal malabsorption * Those who had used any investigational drug within 30 days before the Day 1 visit.